Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 16, 2015

Primary Completion Date

January 3, 2017

Study Completion Date

January 31, 2017

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Nintedanib

Nintedanib 150mg bid

DRUG

Pirfenidone

Trial Locations (23)

20123

Osp. S. Giuseppe Fatebenefratelli, Milan

29406

Lowcountry Lung and Crit Care, Charleston

29609

HOP de la Cavale Blanche, Brest

35033

HOP Pontchaillou, Rennes

45239

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen

53100

A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena

55407

Minnesota Lung Center, Minneapolis

59037

HOP Calmette, Lille

63017

The Lung Research Center, LLC, Chesterfield

69126

Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg

69677

HOP Louis Pradel, Bron

70112

Tulane University Hospital and Clinic, New Orleans

75018

HOP Bichat, Paris

93009

HOP Avicenne, Bobigny

93093

Klinik Donaustauf, Donaustauf

95124

A.O.U. Policlinico Vittorio Emanuele, Catania

06810

Western CT Medical Group, P.C., Danbury

37232-5735

Vanderbilt University Medical Center, Nashville

V6Z 1Y6

St. Paul's Hospital, Vancouver

R2K 3S8

Concordia Hospital, Winnipeg

06001

HOP Pasteur, Nice

3435 CM

Sint Antonius Ziekenhuis, Nieuwegein

3015 CE

Erasmus Medisch Centrum, Rotterdam

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY